Larry J. Schaaf, PhD

Articles by Larry J. Schaaf, PhD

Alternative Dosing Schedules for Irinotecan

ByMace L. Rothenberg, MD,John G. Kuhn, PharmD,Larry J. Schaaf, PhD,Ronald L. Drengler, MD,S. Gail Eckhardt, MD,Miguel A. Villalona-calero, MD,Eric K. Rowinsky, MD,Daniel D. Von Hoff, MD,Langdon L. Miller, MD,Rrobert G. Petit, PhD,Lisa Hammond, MD

August 1st 1998

Most of the clinical experience with irinotecan (CPT-11 [Camptosar]) has been with either a weekly or an every-3-week schedule. Recent phase I trials have explored new routes and schedules of administration. One approach

Latest Updated Articles

Alternative Dosing Schedules for Irinotecan
Published: August 1st 1998 | Updated:

Larry J. Schaaf, PhD

Articles by Larry J. Schaaf, PhD

Alternative Dosing Schedules for Irinotecan

Latest Updated Articles

Trending on CancerNetwork

FDA Approves Adjuvant Cemiplimab in Cutaneous Squamous Cell Carcinoma

Managing BCMA/GPRC5D-Associated CRS and ICANS in the Real-World Setting

Adjuvant Endocrine/Radiation Therapy May Limit Breast Cancer Recurrence

Cryoablation Regimen Receives FDA Marketing Authorization for Breast Cancer

Proactive Psycho-Social Support May Improve Mental Health in Oncology Care